Advanced search
Publication Cover
Leukemia & Lymphoma Volume 53, 2012 - Issue 6
Submit an article Journal homepage
463
Views
7
CrossRef citations to date
0
Altmetric
Letters

A meta-analysis of TET2 mutations shows a distinct distribution pattern in de novo acute myeloid leukemia and chronic myelomonocytic leukemia

Begoña EubaDepartment of Genetics, School of Sciences, University of Navarra, Pamplona, Navarra, Spain
,
José L. VizmanosDepartment of Genetics, School of Sciences, University of Navarra, Pamplona, Navarra, Spain
,
Marta García-GraneroDepartment of Genetics, School of Sciences, University of Navarra, Pamplona, Navarra, Spain
,
Paula AranazDepartment of Genetics, School of Sciences, University of Navarra, Pamplona, Navarra, Spain
,
Cristina HurtadoDepartment of Genetics, School of Sciences, University of Navarra, Pamplona, Navarra, Spain
,
Itziar MiguelizDepartment of Genetics, School of Sciences, University of Navarra, Pamplona, Navarra, Spain
,
Francisco J. NovoDepartment of Genetics, School of Sciences, University of Navarra, Pamplona, Navarra, Spain
&
Marina García-DelgadoDepartment of Genetics, School of Sciences, University of Navarra, Pamplona, Navarra, SpainCorrespondence[email protected]
 show all
Pages 1230-1233 | Received 06 Apr 2011, Accepted 06 Nov 2011, Published online: 02 Apr 2012

References

  • Saint-Martin C, Leroy G, Delhommeau F, . Analysis of the Ten-Eleven Translocation 2 (TET2) gene in familial myeloproliferative neoplasms. Blood 2009;114:1628–1632.
  • Szpurka H., Jankowska AM, Makishima H, . Spectrum of mutations in RARS-T patients includes TET2 and ASXL1 mutations. Leuk Res 2010;34:969–973.
  • Nibourel O, Kosmider O, Cheok M, . Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission. Blood 2010;116:1132–1135.
  • Kohlmann A, Grossmann V, Klein H-U, . Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. J Clin Oncol 2010;28:3858–3865.
  • Colaizzo D, Tiscia GL, Pisanelli D, . New TET2 gene mutations in patients with myeloproliferative neoplasms and splanchnic vein thrombosis. J Thromb Haemost 2010;8:1142–1144.
  • Rocquain J, Carbuccia N, Trouplin V, . Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias. BMC Cancer 2010;10:401.
  • Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 2010;24:1128–1138.
  • Abdel-Wahab O, Manshouri T, Patel J, . Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res 2010;70:447–452.
  • Smith AE, Mohamedali AM, Kulasekararaj A, . Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low abundance mutant clones with early origins, but indicates no definite prognostic value. Blood 2010;116:3923–3932.
  • Ko M, Huang Y, Jankowska AM, . Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 2010;468:839–843.
  • Pollyea DA, Raval A, Kusler B, . Impact of TET2 mutations on mRNA expression and clinical outcomes in MDS patients treated with DNA methyltransferase inhibitors. Hematol Oncol 2011;29:157–160.
  • Bacher U, Haferlach C, Schnittger S, . Mutations of the TET2 and CBL genes: novel molecular markers in myeloid malignancies. Ann Hematol 2010;89:643–652.
  • Metzeler KH, Maharry K, Radmacher MD, . TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2011;29:1373–1381.
  • Tahiliani M, Koh KP, Shen Y, . Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 2009;324:930–935.
  • Holmfeldt L, Mullighan CG. The role of TET2 in hematologic neoplasms. Cancer Cell 2011;20:1–2.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.